IMARC Group, a leading market research company, has recently releases report titled “Central Nervous System Therapeutics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028.” The study provides a detailed analysis of the industry, including the global central nervous system therapeutics market report, growth, share, size, trends, and forecasts. The report also includes competitor and regional analysis and highlights the latest advancements in the market.
Industry Overview of Central Nervous System Therapeutics Market
Central nervous system (CNS) therapeutics are treatment solutions that are designed to target and address disorders that affect CNS in the body. They comprise anesthetics, anticonvulsants, CNS stimulants, muscle relaxants, antidepressants, narcotic analgesics, and sedatives. They assist in slowing down disease progression and alleviating symptoms among patients. As they are utilized to treat epilepsy, cancers, multiple sclerosis, Parkinson’s disease, depression, anxiety, Huntington’s disease, and Alzheimer’s disease among individuals, the demand for CNS therapeutics is increasing across the globe.
How Big Is the Central Nervous System Therapeutics Market?
The global central nervous system (CNS) therapeutics market size reached US$ 131.2 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 214.6 Billion by 2028, exhibiting a growth rate (CAGR) of 6.8% during 2023-2028.
Global Industry Trends and Drivers:
At present, the rising prevalence of mental illness and lifestyle-associated CNS disorders among the masses around the world represents one of the primary factors strengthening the market growth. Besides this, the growing adoption of CNS therapeutics due to the increasing psychological distress among the young population worldwide is offering a positive market outlook. Apart from this, the rising awareness among individuals about various CNS disorders and their effective therapeutic options is contributing to the growth of the market. Moreover, the increasing demand for CNS therapeutics among the geriatric population, as they are more prone to neurological disorders, is offering lucrative growth opportunities to industry investors. Furthermore, various technological advancements in drug delivery systems, such as the introduction of transdermal patches for CNS disorders to provide an accurate amount of medicine and relief to patients, are impelling the market growth.
What Is Included in Market Segmentation?
The report has segmented the market into the following categories:
Breakup by Disease:
- Neurodegenerative Diseases
- Alzheimer’s Disease
- Parkinson’s Disease
- Multiple Sclerosis
- Huntington’s Disease
- Amyotrophic Lateral Sclerosis
- Others
- Neurovascular Diseases
- CNS Trauma
- Mental Health
- Anxiety Disorders
- Epilepsy
- Mood Disorders
- Psychotic Disorders
- Others
- Infectious Diseases
- CNS Cancer
- Others
Breakup by Application:
- Hospital
- Clinic
- Homecare
- Others
Breakup by Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Who are the key players operating in the industry?
AstraZeneca plc, Biogen Inc., Eli Lilly and Company, F. Hoffmann-La Roche AG (Roche Holding), H. Lundbeck A/S, Merck & Co. Inc., Neurocrine Biosciences Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited and Teva Pharmaceutical Industries Ltd.